Brain cancer treatment.
Holistic patient care and innovative research
18 March 2019
Sechenov University
15:00 —16:30
lecture in Moscow
The Rotterdam Erasmus MC Brain Tumor Centre
The Erasmus MC Brain Tumor Center (BTC) is the first multidisciplinary expertise center for brain tumor patients in the Netherlands, with one goal: to improve the quality of life and survival of brain tumor patients. The BTC team focuses on the patient and their personal situation from diagnosis, treatment and follow-up. Individual treatment plans are made in consultation with the patient and are discussed in a twice-weekly brain tumor board. Patients are treated according to multidisciplinary care paths and specialized nurses ensure continuity.

In addition the BTC focuses on translational research with a direct influence on the diagnosis, prognosis and/or treatment of brain tumor patients. Research lines focus on omics, tumor models, developing drugs screen logistics and new treatments, including (viro-)immunotherapy. Therefore BTC researchers work together on a local, national and international level. The BTC is strongly involved in the European Organization for Research and Treatment of Cancer (the EORTC) and has close links with leading brain tumor institutes throughout the world.

Nick Guldemond
Associate Professor Integrated Care & Technology, Institute of Health Policy & Management of Erasmus University Rotterdam Dr. Guldemond has a background in electric engineering and medicine. He is a key expert on eHealth and integrated care for various international organisations such as WHO Global eHealth Observatory, EU Programmes as European initiative on Healthy and Active Ageing, Knowledge Innovation Community (KIC) Health and KIC Digital, Ambient Assisted Living, Innovative Medicine Initiative and Innovative Medical Device Initiative. He is advisor on eHealth and healthcare transformation for various national/regional eHealth institutes NHS UK, NHS Scotland, Norway, China, Poland, Germany, Belgium as well as multinational companies in Pharma (Roche, Novartis, Genzyme), Medtech (Philips, MEDTRONIC), health IT (Microsoft, Ascom, Ortec, Vodafone) and finance (Rabobank, Natwest, RBS). Dr. Guldemond is on behalf of the Netherlands Federation of University Medical Centres (NFU) architect of the national eHealth implementation research agenda and health track leader of the big data alliance.
Walter Taal
Walter Taal works as a neurologist at the Neuro-Oncology department of the Erasmus MC Cancer Institute (Rotterdam, The Netherlands) since 2002. This department focuses on diseases of the central and peripheral nervous system caused by cancer or by the treatment of cancer. Special interest of Walter Taal goes to gliomas, spinal metastases and neurofibromatosis type I. Walter Taal is involved in various international (EORTC) studies on the effect of antineoplastic agents in gliomas. He defended his PhD thesis "Chemotherapy in Glioma" on 30 October 2015 in Rotterdam. Furthermore he is a management member of the Dutch Neuro-Oncology Group, participates in the Dutch national neuro-oncology rare tumor group, is the chairman of the Dutch national guideline work group on spinal metastasis and a member of the medical advisory board of the Dutch Neurofibromatosis Association. Walter Taal teaches neurologists (in training), medicine students and nurses in the entire field of neuro-oncology .
Clemens Dirven
Professor and Chair of the department of Neurosurgery Erasmus University Medical Center. After studying medicine in Nijmegen, he trained as a neurosurgeon at the Acadermisch Hospital in Groningen. He also started his research on brain tumors and he obtained his doctorate for a thesis on a benign type of brain tumor that occurs in children. He then worked for 11 years as a neurosurgeon in the VU Medical Center Amsterdam, where he became a professor in the field of brain tumor research. Prof. Dirven is a co-founder and co-director of the Erasmus Brain Tumor Center and a member of the Netherlands Commission of Genetic Modification (COGEM).
In his research he focuses on new therapies for malignant braintumors, viro-immunotherapy and development of braintumor models.
Monday, 18 March 2019, 15:00
Sechenov University
The registration is closed